Who is sponsoring NCT03698552?

NCT03698552 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT03698552?

Interventions in NCT03698552: ADCT-602.

What condition does NCT03698552 study?

NCT03698552 studies Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia.

Is NCT03698552 still recruiting?

NCT03698552 is currently terminated. Last updated 12 December 2025.

Last reviewed 2025-12-12 · How we verify

NCT03698552

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Terminated Phase 1, PHASE2 Last updated 12 December 2025

What this trial tests

Phase 1, PHASE2 trial testing ADCT-602 in Blasts 5 Percent or More of Bone Marrow Nucleated Cells in 37 participants. Terminated before completion.

Timeline

24 August 2018

Primary endpoint
6 November 2025

6 November 2025

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	24 August 2018
Primary completion	6 November 2025
Estimated completion	6 November 2025
Sites	2 locations across United States

Drugs / interventions tested

ADCT-602 — full drug profile →

Conditions studied

Blasts 5 Percent or More of Bone Marrow Nucleated Cells — all drugs for Blasts 5 Percent or More of Bone Marrow Nucleated Cells →
CD22 Positive — all drugs for CD22 Positive →
Philadelphia Chromosome Positive — all drugs for Philadelphia Chromosome Positive →
Recurrent B Acute Lymphoblastic Leukemia — all drugs for Recurrent B Acute Lymphoblastic Leukemia →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Blasts 5 Percent or More of Bone Marrow Nucleated Cells or CD22 Positive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial studies the side effects and best dose of ADCT-602 in treating patients with B-cell lymphoblastic leukemia that has come back or does not respond to treatment. Monoclonal antibodies, such as ADCT-602, may interfere with the ability of tumor cells to grow and spread.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U, Parakh S, Gan HK, Scott AM. · · 2020 · cited 283× · PMID 33081383 · DOI 10.3390/molecules25204764
Targeting cancer with antibody-drug conjugates: Promises and challenges.
Dean AQ, Luo S, Twomey JD, Zhang B. · · 2021 · cited 145× · PMID 34291723 · DOI 10.1080/19420862.2021.1951427
The Evolving Landscape of Antibody-Drug Conjugates: In Depth Analysis of Recent Research Progress.
Sasso JM, Tenchov R, Bird R, Iyer KA, et al · · 2023 · cited 89× · PMID 37821099 · DOI 10.1021/acs.bioconjchem.3c00374
Targeting CD22 for the Treatment of B-Cell Malignancies.
Shah NN, Sokol L. · · 2021 · cited 42× · PMID 34262884 · DOI 10.2147/itt.s288546
Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy.
Ren X, Lin S, Guan F, Kang H. · · 2024 · cited 30× · PMID 38725856 · DOI 10.7150/ijbs.93806
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults.
Saleh K, Fernandez A, Pasquier F. · · 2022 · cited 24× · PMID 35406576 · DOI 10.3390/cancers14071805
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences.
Barreca M, Lang N, Tarantelli C, Spriano F, et al · · 2022 · cited 23× · PMID 36654819 · DOI 10.37349/etat.2022.00112
Antibody-Drug Conjugates for the Treatment of Acute Pediatric Leukemia.
Stokke JL, Bhojwani D. · · 2021 · cited 19× · PMID 34441852 · DOI 10.3390/jcm10163556

Verify or expand the search:

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03698552 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 12 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03698552.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing